<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20067974</article-id><article-id pub-id-type="pmc">2845014</article-id><article-id pub-id-type="publisher-id">1867</article-id><article-id pub-id-type="doi">10.2337/dc09-1867</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>Bo</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Foley</surname><given-names>James E.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferrannini</surname><given-names>Ele</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Matthews</surname><given-names>David R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zinman</surname><given-names>Bernard</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dejager</surname><given-names>Sylvie</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fonseca</surname><given-names>Vivian A.</given-names></name><degrees>MD, FRCP</degrees><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Medicine, Lund University, Lund, Sweden; </aff><aff id="aff2"><sup>2</sup>Novartis Pharmaceuticals, East Hanover, New Jersey; </aff><aff id="aff3"><sup>3</sup>Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa, Pisa, Italy; </aff><aff id="aff4"><sup>4</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital and National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, U.K.; </aff><aff id="aff5"><sup>5</sup>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; </aff><aff id="aff6"><sup>6</sup>Clinical Research, Novartis Pharma SAS, Rueil-Malmaison, France; </aff><aff id="aff7"><sup>7</sup>Department of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Bo Ahr&#x000e9;n, <email>bo.ahren@med.lu.se</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2010</year></pub-date><volume>33</volume><issue>4</issue><fpage>730</fpage><lpage>732</lpage><history><date date-type="received"><day>8</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2010 by the American Diabetes Association.</copyright-statement><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00410000730.pdf"/><abstract><sec><title>OBJECTIVE</title><p>To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in a trial evaluating add-on therapy to metformin with 50 mg vildagliptin b.i.d. compared with glimepiride up to 6 mg q.d. in type 2 diabetes (baseline A1C 7.3 &#x000b1; 0.6%).</p></sec><sec><title>RESULTS</title><p>A1C and prandial glucose area under the curve (AUC)<sub>0&#x02013;2 h</sub> were reduced similarly in both groups, whereas prandial insulin AUC<sub>0&#x02013;2 h</sub> increased to a greater extent by glimepiride. Prandial glucagon AUC<sub>0&#x02013;2 h</sub> (baseline 66.6 &#x000b1; 2.3 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup>) decreased by 3.4 &#x000b1; 1.6 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> by vildagliptin (<italic>n</italic> = 137) and increased by 3.8 &#x000b1; 1.7 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> by glimepiride (<italic>n</italic> = 121). The between-group difference was 7.3 &#x000b1; 2.1 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> (<italic>P</italic> &#x0003c; 0.001).</p></sec><sec><title>CONCLUSIONS</title><p>Vildagliptin therapy but not glimepiride improves postprandial &#x003b1;-cell function, which persists for at least 2 years.</p></sec></abstract></article-meta></front><body><p>Glucagon levels are increased in type 2 diabetes because of impaired glucose-mediated suppression of glucagon secretion resulting in increased hepatic glucose output with subsequent hyperglycemia (<xref ref-type="bibr" rid="B1">1</xref>). Improved glycemia by the dipeptidyl peptidase-4 inhibitor, vildagliptin (<xref ref-type="bibr" rid="B2">2</xref>), is mediated primarily by improved &#x003b2;- and &#x003b1;-cell sensitivity to glucose (<xref ref-type="bibr" rid="B3">3</xref>). As an add-on to metformin, vildagliptin displays equal efficacy as glimepiride, with the added benefits of a much lower risk of hypoglycemia and no weight gain (<xref ref-type="bibr" rid="B4">4</xref>). Here we report prandial assessments of glucagon levels and insulin secretion rates after up to &#x0223c;2 years of therapy with the two drugs.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>The study was an extension to 2 years of a previously described study (<xref ref-type="bibr" rid="B4">4</xref>). Standard meal challenge was performed in selected centers at last treatment visit after administration of a morning dose of metformin plus 50 mg vildagliptin or up to 6 mg glimepiride (mean treatment period 1.8 years). Doses were selected to achieve comparable improvements in glycemia. After an overnight fast, a mixed meal was served (orange juice [180 ml], two slices [60 g] of white bread, 30 g jam, 15 g butter or margarine, 120 ml whole milk [3&#x02013;4% fat] or equivalent amount of cheese plus 120 ml water, and, if desired, decaffeinated coffee or tea; 510 kcal, with 50% from carbohydrate, 38% from fat, and 12% from protein). Blood samples were taken before the meal and at 15, 30, 60, 90, 120, 180, and 240 min.</p><sec><title>Analytical determinations</title><p>Plasma glucose concentration was determined by the glucose oxidase method (Beckman Glucose Analyzer II; Beckman Instruments, Fullerton, CA). Plasma insulin, C-peptide, and glucagon concentrations were determined by radioimmunoassay (Diagnostics Products, Los Angeles, CA). Plasma intact glucagon-like peptide (GLP)-1 concentration was measured by ELISA using an NH<sub>2</sub>-terminal&#x02013;specific antibody (Linco Research, St. Charles, MO) by Novartis.</p></sec><sec><title>Calculations</title><p>Insulin secretory rate was determined as described previously (<xref ref-type="bibr" rid="B5">5</xref>). The absolute and incremental/decremental areas under the curve (AUCs) for time 0&#x02013;2 h after the meal were calculated using the trapezoidal method. End point changes from baseline were assessed using ANCOVA.</p></sec><sec><title>Ethics</title><p>The study was conducted in accordance with the Declaration of Helsinki. It was reviewed by an independent ethics committee or institutional review board for each center. Written informed consent was obtained from each subject.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Baseline characteristics were as follows: patient demographics of the subpopulation who participated in the meal challenge (<italic>n</italic> = 259) were essentially the same as reported previously (<xref ref-type="bibr" rid="B4">4</xref>). Mean baseline A1C was 7.3 &#x000b1; 0.6%.</p><sec><title>A1C, glucose, and insulin</title><p>At the follow-up meal test (up to 2 years after start; mean 1.8 years), A1C was reduced by &#x02212;0.1 &#x000b1; 0.9% in the vildagliptin group (<italic>n</italic> = 137) versus &#x02212;0.2 &#x000b1; 0.8% in the glimepiride group (<italic>n</italic> = 121). Prandial glucose AUC<sub>0&#x02013;2 h</sub> was similarly reduced in both groups (&#x02212;1.7 mmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for vildagliptin vs. &#x02212;2.1 mmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for glimepiride), whereas prandial insulin 1 AUC<sub>0&#x02013;2 h</sub> increased to a greater extent in the glimepiride group (33 &#x000b1; 18 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for vildagliptin vs. 91 &#x000b1; 19 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for glimepiride) (<italic>P</italic> = 0.017).</p></sec><sec><title>Glucagon, GLP-1, and insulin secretion</title><p>Prandial glucagon AUC<sub>0&#x02013;2 h</sub> decreased from baseline with vildagliptin treatment but increased with glimepiride (&#x02212;3.4 &#x000b1; 1.6 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for vildagliptin vs. 3.8 &#x000b1; 1.7 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for glimepiride; <italic>P</italic> &#x0003c; 0.001; <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>). Prandial intact GLP-1 AUC<sub>0&#x02013;2 h</sub> increased in both groups but was much larger after vildagliptin (18.8 &#x000b1; 1.8 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for vildagliptin vs. 1.6 &#x000b1; 1.7 pmol &#x000b7; h<sup>&#x02212;1</sup> &#x000b7; l<sup>&#x02212;1</sup> for glimepiride; <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>). Insulin secretion rate relative to glucose (0&#x02013;2 h) increased in both groups (4.3 &#x000b1; 0.9 pmol/min/m<sup>2</sup>/mmol/l for glimepiride vs. 1.6 &#x000b1; 0.9 pmol/min/m<sup>2</sup>/mmol/l for vildagliptin; <italic>P</italic> = 0.022; <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>). Prandial insulin-to-glucagon ratio (AUC<sub>0&#x02013;2 h</sub> for insulin/AUC<sub>0&#x02013;2 h</sub> for glucagon) changed by &#x02212;1.1 &#x000b1; 9.3 (baseline 7.4 &#x000b1; 0.4) pmol insulin/pmol glucagon in the vildagliptin group versus &#x02212;7.3 &#x000b1; 9.8 (baseline 7.1 &#x000b1; 0.4) pmol insulin/pmol glucagon in the glimepiride group (<italic>P</italic> = 0.62).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Changes in prandial glucagon AUC<sub>0&#x02013;2 h</sub>, prandial GLP-1 AUC<sub>2 h</sub>, insulin secretory rate relative to glucose (ISR/G), and HOMA-IR after up to a 2-year (mean 1.8 years) add-on treatment with vildagliptin (50 mg b.i.d.; <italic>n</italic> = 137) or glimepiride (up to 6 mg; <italic>n</italic> = 121) in patients with type 2 diabetes inadequately controlled with prior metformin therapy. Means &#x000b1; SD are shown. The asterisk indicates <italic>P</italic> &#x0003c; 0.001 (<italic>A</italic>), <italic>P</italic> &#x0003c; 0.001 (<italic>B</italic>), <italic>P</italic> = 0.022 (<italic>C</italic>), and <italic>P</italic> &#x0003c; 0.001 (<italic>D</italic>) between the groups.</p></caption><graphic xlink:href="zdc0041081520001"/></fig></sec><sec><title>Insulin resistance</title><p>Fasting insulin (15.2 &#x000b1; 1.6 pmol/l for glimepiride vs. 5.7 &#x000b1; 1.6 pmol/l for vildagliptin; <italic>P</italic> &#x0003c; 0.001) and HOMA-IR (0.11 &#x000b1; 0.10 for vildagliptin vs. 0.63 &#x000b1; 0.10 for glimepiride; <italic>P</italic> &#x0003c; 0.001; <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>D</italic>) increased in both treatment groups with larger increases with glimepiride.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Vildagliptin reduces glucagon levels after a standard mixed meal in patients with type 2 diabetes who are treated with metformin, as was previously demonstrated in individuals with IGT (<xref ref-type="bibr" rid="B6">6</xref>), IFG (<xref ref-type="bibr" rid="B7">7</xref>), and type 1 diabetes (<xref ref-type="bibr" rid="B8">8</xref>). This effect appears to be the result of a GLP-1&#x02013;induced improvement in glucose sensitivity of the &#x003b1;-cells (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B9">9</xref>). In contrast, glimepiride increases glucagon levels, which may be the result of attenuation of the glucose sensitivity of the &#x003b1;-cells with uncoupling of glucose dependency (<xref ref-type="bibr" rid="B10">10</xref>).</p><p>With respect to &#x003b2;-cell function, vildagliptin increases glucose sensitivity (<xref ref-type="bibr" rid="B11">11</xref>), whereas indirect data suggest that sulfonylurea uncouples the glucose dependency of the &#x003b2;-cells, which attenuates glucose sensitivity (<xref ref-type="bibr" rid="B10">10</xref>). In this study, this resulted in increased insulin secretion by both treatments, although vildagliptin did not increase the insulin secretion rate as much as glimepiride. The greater insulin secretion rate in the glimepiride group was balanced by less insulin resistance in the vildagliptin group, as reflected by HOMA-IR and lower postprandial glucagon levels resulting in similar glucose levels.</p><p>In summary, prandial glucagon is increased by glimepiride but reduced by vildagliptin. Hence, vildagliptin effectively targets glucagon secretion in the treatment of diabetes. This together with the lesser increase in insulin by vildagliptin than by glimepiride may provide a pathophysiological explanation for the observation that vildagliptin's effect of reducing A1C levels below 7% is associated with much less hypoglycemia than glimepiride while being associated with the same A1C reduction (<xref ref-type="bibr" rid="B4">4</xref>).</p></sec></body><back><fn-group><fn fn-type="other"><p>Clinical trial reg. no. NCT00106340, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This study was funded by Novartis Pharmaceuticals. D.R.M. is a Senior Investigator of the National Institute of Health Research (NIHR), U.K., and acknowledges NIHR funding support. E.F. has received consulting fees from Novartis Pharmaceuticals. V.A.F. has received funding for research and consulting/speaking for Novartis as well as from other manufacturers of drugs in this class, including Merck, Novo-Nordisk, Eli Lilly, Takeda, and Glaxo. B.Z. has received research support and consulting fees from Novartis Pharmaceuticals. B.A. has received funding and consulting fees from Novartis Pharmaceuticals. D.R.M. has received consulting fees from Novartis as well as from other manufacturers of drugs in this class, including Novo-Nordisk and Merck. He has also received lecturing honoraria from Eli Lilly and Novo-Nordisk. J.F. and S. D. are employees of Novartis Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.</p><p>The authors gratefully acknowledge the investigators, those who participated in any part of the study (listed previously in Ferrannini et al. [4]), staff at the 402 participating sites, and the editorial assistance of Gali Venkateswara Prasad and Shivali Arora, PhD (both from Novartis, India).</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balas</surname><given-names>B</given-names></name><name><surname>Baig</surname><given-names>MR</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Ligueros-Saylan</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>YL</given-names></name><name><surname>Darland</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group> <article-title>The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients</article-title>. <source>J Clin Endocrinol Metab</source><year>2007</year>;<volume>92</volume>:<fpage>1249</fpage>&#x02013;<lpage>1255</lpage><pub-id pub-id-type="pmid">17244786</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Landin-Olsson</surname><given-names>M</given-names></name><name><surname>Jansson</surname><given-names>PA</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>D</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name></person-group> <article-title>Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source><year>2004</year>;<volume>89</volume>:<fpage>2078</fpage>&#x02013;<lpage>2084</lpage><pub-id pub-id-type="pmid">15126524</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name></person-group> <article-title>The islet enhancer vildagliptin: mechanisms of improved glucose metabolism</article-title>. <source>Int J Clin Pract Suppl</source><year>2008</year>;<volume>159</volume>:<fpage>8</fpage>&#x02013;<lpage>14</lpage><pub-id pub-id-type="pmid">18269436</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Matthews</surname><given-names>D</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Byiers</surname><given-names>S</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name></person-group> <article-title>Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy</article-title>. <source>Diabetes Obes Metab</source><year>2009</year>;<volume>11</volume>:<fpage>157</fpage>&#x02013;<lpage>166</lpage><pub-id pub-id-type="pmid">19125777</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratley</surname><given-names>RE</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Banerji</surname><given-names>MA</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Mills</surname><given-names>D</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name></person-group> <article-title>Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-na&#x000ef;ve patients: analysis of pooled vildagliptin monotherapy database</article-title>. <source>Diabetes Obes Metab</source><year>2008</year>;<volume>10</volume>:<fpage>931</fpage>&#x02013;<lpage>938</lpage><pub-id pub-id-type="pmid">18093207</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Rendell</surname><given-names>M</given-names></name><name><surname>Landin-Olsson</surname><given-names>M</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Rochotte</surname><given-names>E</given-names></name><name><surname>Baron</surname><given-names>MA</given-names></name></person-group> <article-title>Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance</article-title>. <source>Diabetes Care</source><year>2008</year>;<volume>31</volume>:<fpage>30</fpage>&#x02013;<lpage>35</lpage><pub-id pub-id-type="pmid">17947341</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzschneider</surname><given-names>KM</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Udayasankar</surname><given-names>J</given-names></name><name><surname>Gerchman</surname><given-names>F</given-names></name><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Watson</surname><given-names>CE</given-names></name><name><surname>Ligueros-Saylan</surname><given-names>MA</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Kahn</surname><given-names>SE</given-names></name></person-group> <article-title>The dipeptidyl peptidase-4 inhibitor vildagliptin improves &#x003b2;-cell function and insulin sensitivity in subjects with impaired fasting glucose</article-title>. <source>Diabetes</source><year>2008</year>;<volume>31</volume>:<fpage>108</fpage>&#x02013;<lpage>113</lpage></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Ligueros-Saylan</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>YL</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Leone-Jones</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Kelley</surname><given-names>DE</given-names></name></person-group> <article-title>Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes</article-title>. <source>Horm Metab Res</source><year>2008</year>;<volume>40</volume>:<fpage>727</fpage>&#x02013;<lpage>730</lpage><pub-id pub-id-type="pmid">18597213</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Nilsson</surname><given-names>PM</given-names></name><name><surname>Persson</surname><given-names>M</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name></person-group> <article-title>Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source><year>2009</year>;<volume>94</volume>:<fpage>1236</fpage>&#x02013;<lpage>1243</lpage><pub-id pub-id-type="pmid">19174497</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Heer</surname><given-names>J</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group> <article-title>Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1</article-title>. <source>Diabetes</source><year>2007</year>;<volume>56</volume>:<fpage>438</fpage>&#x02013;<lpage>443</lpage><pub-id pub-id-type="pmid">17259389</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Scherbaum</surname><given-names>WA</given-names></name><name><surname>Nilsson</surname><given-names>PM</given-names></name><name><surname>Lalanne</surname><given-names>G</given-names></name><name><surname>Schweizer</surname><given-names>A</given-names></name><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Jauffret</surname><given-names>S</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name></person-group> <article-title>Characterization of the influence of vildagliptin on model-assessed &#x003b2;-cell function in patients with type 2 diabetes and mild hyperglycemia</article-title>. <source>J Clin Endocrinol Metab</source><year>2008</year>;<volume>93</volume>:<fpage>103</fpage>&#x02013;<lpage>109</lpage><pub-id pub-id-type="pmid">17925336</pub-id></mixed-citation></ref></ref-list></back></article>